-- Days : -- HRS : -- MIN : -- SEC
Register Now →

All News

Bristol Myers Squibb announced the commercial launch of Zeposia (ozanimod) for relapsing multiple sclerosis (RMS). The oral treatment is the first and only approved sphingosine-1-phosphate receptor modulator with no genetic test or first dose observation at initiation.

Research has established an association between social risk factors and child health outcomes, while professional medical organizations have endorsed screening for such factors in clinical settings. Providing an in-person patient navigator to address family social needs leads to a decrease in child health care utilization, according to a study published in JAMA Network Open.